Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 millionYAVNE,…
WALTHAM, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a…
SEATTLE, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to…
In 2023, Cosmos Health concluded multiple acquisitions, including Cana Laboratories, the distribution network owned by Bikas GP, and ZipDoctor.These acquisitions…
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - December 27, 2023) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV)…
- Primary Endpoint of Safety and Efficacy Met with Clinical Activity and Increased Survival Observed - - 70.3 Weeks Median…
Company to retain economic interest in biotherapeutic asset while removing cash burn from development and commercialization costsREDWOOD CITY, Calif., Dec.…
In an acute colitis model, data show statistically significant knockdown of elevated levels of serum TNFα, reductions in tissue TNFα…
No dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric oxide administered at 25,000 parts…
Statistically Significant and Clinically Meaningful Increasein Primary Efficacy Endpoint at 24 Weeks of Treatment; Improvement Consistent Across All Prespecified Subgroups…